Clinical Trial Update: Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects [Phase 2]

View source ↗

Summary

Open-label extension study (OLE) of Velneperit (S-2367) in obese subjects completed, evaluating safety and efficacy in Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Velneperit (S-2367) (Velneperit)

Snippet

Sponsor: Shionogi | Conditions: Obesity | Phase 2 | Status: COMPLETED